advanced squamous non-small-cell lung cancer
Conditions
Interventions
induction therapy with carboplatin plus albumin-bound paclitaxel, and following S-1 maintenance therapy
Sponsors
Hamamatsu University School of Medicine
Iwata general hospital, Shizuoka general hospital, Ensyu hospital, Shizuoka red-cross hospital, Shizuoka city Shizuoka hospital, Shizuoka city Shimizu hospital, Seirei Mikatahara general hospital, Seirei Hamamatsu general hospital, Tenryu hospital, Hamamatsu red-cross hospital, Hamamatsu Rosai hospital, Hamamatsu medical center, Fujieda city hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) pathologically or cytologically diagnosed as squamous NSCLC 2) clinical stage IIIB, IV or relapse 3) ECOG PS of 0-1 4) expectation of at least 3 months of survival after study therapy 5) existence of measurable lesion 6) capability of oral intake 7) adequate organ function 8) written informed consent given
Exclusion criteria
Exclusion criteria: 1) history of pyrimidine-based chemotherapy 2) symptomatic brain metastasis (asymptomatic cases after treatments are allowed) 3) fluid retention that needs to be controlled 4) watery diarrhea 5) severe comorbidities 6) active cancers in other organs 7) existence and/or willing to pregnancy 8) psychological disorder incapable of entry for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS measured from start of the maintenance therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| OS, PFS measured from the enrollment, response rate, disease control rate in the induction therapy, safety | — |
Countries
Japan
Contacts
Public ContactMasato Karayama
Hamamatsu Univ. School of Medicine Department of clinical oncology
Outcome results
None listed